FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference20 articles.
1. 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001;Hamid;J Clin Oncol,2018
2. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019
3. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N Engl J Med,2019
4. The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy;Wong;Eur J Nucl Med Mol Imaging,2017
5. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma;Tan;Ann Oncol,2018
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The impact of introducing deep learning based [18F]FDG PET denoising on EORTC and PERCIST therapeutic response assessments in digital PET/CT;EJNMMI Research;2024-08-10
2. Multimodal Imaging Approach for Tumor Treatment Response Evaluation in the Era of Immunotherapy;Investigative Radiology;2024-07-17
3. Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis;eClinicalMedicine;2024-07
4. Immunotherapy Response and Resistance in Patients with Advanced Uveal Melanoma;2024-06-25
5. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma;European Journal of Cancer;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3